# PAQ Therapeutics Presents First Clinical Data for PT0253, a Selective KRAS G12D Degrader, Showing a Differentiated Safety Profile and Antitumor Activity at ENA 2026

- Source: PR Newswire M&A
- Published: 2026-11-20T12:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/paq-therapeutics-presents-first-clinical-data-for-pt0253-a-selective-kras-g12d-degrader-showing-a-differentiated-safety-profile-and-antitumor-activity-at-ena-2026-302939854.html
- Canonical: https://groundlevelnews.com/story/paq-therapeutics-presents-first-clinical-data-for-pt0253-a-selective-k-76bf5f/

– No dose-limiting toxicities observed across doses from 10 to 750 mg, with no PT0253-specific pre-treatment prophylaxis required – – Monotherapy antitumor activity observed in colorectal and pancreatic cancers, including a partial response in a patient previously treated with a...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._
